title: Impact of short-term treatment with telmisartan on cerebral arterial remodeling in SHR.
abstract: OBJECTIVE
  Chronic hypertension decreases internal diameter of cerebral arteries and arterioles. We recently showed that short-term treatment with the angiotensin II receptor blocker telmisartan restored baseline internal diameter of small cerebral arterioles in spontaneously hypertensive rats (SHR), via reversal of structural remodeling and inhibition of the angiotensin II vasoconstrictor response. As larger arteries also participate in the regulation of cerebral circulation, we evaluated whether similar short-term treatment affects middle cerebral arteries of SHR.
  
  
  METHODS
  Baseline internal diameters of pressurised middle cerebral arteries from SHR and their respective controls, Wistar Kyoto rats (WKY) and responses to angiotensin II were studied in a small vessel arteriograph. Pressure myogenic curves and passive internal diameters were measured following EDTA deactivation, and elastic modulus from stress-strain relationships.
  
  
  RESULTS
  Active baseline internal diameter was 23% lower in SHR compared to WKY, passive internal diameter (EDTA) 28% lower and elastic modulus unchanged. Pressure myogenic curves were shifted to higher pressure values in SHR. Telmisartan lowered blood pressure but had no effect on baseline internal diameter nor on structural remodeling (passive internal diameter and elastic modulus remained unchanged compared to SHR). Telmisartan shifted the pressure myogenic curve to lower pressure values than SHR.
  
  
  CONCLUSIONS
  In the middle cerebral arteries of SHR, short-term treatment with telmisartan had no effect on structural remodeling and did not restore baseline internal diameter, but allowed myogenic tone to adapt towards lower pressure values.
authors.affiliation: Université de Lorraine, CITHÉFOR "Drug targets, formulation and preclinical assessment," EA3452, Faculté de Pharmacie, Nancy, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Foulquier
authors.affiliation: Université de Lorraine, CITHÉFOR "Drug targets, formulation and preclinical assessment," EA3452, Faculté de Pharmacie, Nancy, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lartaud
authors.affiliation: Université de Lorraine, CITHÉFOR "Drug targets, formulation and preclinical assessment," EA3452, Faculté de Pharmacie, Nancy, France.
authors.forename: François
authors.initials: F
authors.lastname: Dupuis
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D064752:Atrial Remodeling / Q000187:drug effects*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D001565:Benzoates / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002536:Cerebral Arteries / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D020768:Middle Cerebral Artery / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D011918:Rats, Inbred SHR; D000077333:Telmisartan; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan